Stevenage, UK; 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors. In addition, Dr Iraj Ali, currently Interim CEO, will become the permanent, full-time CEO of the Company. […]
This author has yet to write their bio.Meanwhile lets just say that we are proud achilles contributed a whooping 2 entries.
Entries by achilles
Stevenage, 19 September 2018 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens, today announced that it has appointed senior pharmaceutical executive Michael F. Giordano, M.D., to its Board of Directors. Dr. Iraj Ali, Achilles’ Chief Executive Officer, commented: “We are delighted to welcome Michael Giordano to our Board of […]